‘A completely new person’: can surgery help Alzheimer’s patients regain basic skills?

These scenarios are written by an AI language model from the headline and summary above. They are not predictions from the newsroom, and they are not evidence of anything. Every one is given a deadline and checked against later coverage, and the score is published on the ledger — including the ones that miss.

• Awaiting deadline 45% Regulatory Approval and Commercial Rollout

  Following successful Phase III trial results, the Hong Kong Medical Products Regulatory Authority grants provisional approval for the procedure, allowing CUHK and mainland partners to begin commercializing the treatment. Major pharmaceutical investors secure rights to distribute the protein-drainage technology globally, establishing a new standard of care for moderate Alzheimer's patients.

  Watch for: Hong Kong’s Medical Products Regulatory Authority issues provisional marketing authorization for CUHK’s Alzheimer’s surgical procedure · Major pharmaceutical company announces multi-billion dollar licensing deal for CUHK’s protein-drainage technology

• Awaiting deadline 30% Safety Crisis and Trial Suspension

  A cluster of serious adverse events, including post-operative infections or unintended cognitive decline, occurs among trial participants. This triggers an immediate suspension of the clinical trial by independent ethics boards and prompts investigations by health authorities in both Hong Kong and mainland China, casting doubt on the procedure's safety profile.

  Watch for: Independent ethics board suspends CUHK Alzheimer’s trial after three patients suffer severe post-operative complications · Chinese National Medical Products Administration launches investigation into safety protocols of Hangzhou-origin brain surgery technique

• Awaiting deadline 15% Geopolitical IP Dispute and Stagnation

  Tensions rise between Hong Kong and mainland Chinese stakeholders over intellectual property rights regarding the 2018 innovation, leading to legal injunctions that freeze the clinical trial. The resulting uncertainty causes key funding to dry up, stalling development and pushing rival institutions in Japan and the US to accelerate their own competing treatments.

  Watch for: Chinese court issues injunction halting CUHK’s Alzheimer’s trial pending resolution of IP ownership dispute · CUHK announces indefinite pause in clinical trials due to unresolved legal conflicts with mainland partners

• Awaiting deadline 10% Paradigm Shift via Non-Invasive Alternative

  A competing non-invasive therapy, utilizing gene editing or advanced immunotherapy, demonstrates equal or superior efficacy in early trials without surgical risks. This renders the invasive protein-drainage procedure obsolete in the eyes of major funding bodies, who redirect resources away from CUHK’s surgical model toward the less risky alternative.

  Watch for: FDA grants breakthrough therapy designation to non-invasive gene therapy for Alzheimer’s, overshadowing surgical approaches · Global Alzheimer’s research consortium shifts majority of funding away from surgical interventions toward immunotherapy trials

Generated by Qwen3.6-35B-A3B-UD-Q5_K_M.gguf on 2026-08-03. Checked against later coverage after 2028-01-25. See how these forecasts score.